Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

919
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
919
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

6.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.9K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

652
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
652
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

26
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
26
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

7.1K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
7.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Protein exosites as drug targets: from structural topology to therapeutic modality.

Drug discovery today·2026
Same author

Citrus Flavonoids-Coated Biogenic Nanoparticles for Controlling <i>Xanthomonas axonopodis</i> pv. <i>citri</i>: Antimicrobial Efficacy and NMR-Based Investigation of Bacterial Metabolic Reprogramming.

ACS applied bio materials·2025
Same author

Accessing Altered Metabolic Profile in Acute Deep Vein Thrombosis Through Nuclear Magnetic Resonance Spectroscopy.

International journal of molecular sciences·2025
Same author

Artificial Intelligence-Based Methods and Omics for Mental Illness Diagnosis: A Review.

Bioengineering (Basel, Switzerland)·2025
Same author

STINGAllo: a web server for high-throughput prediction of allosteric site-forming residues using internal protein nanoenvironment descriptors.

Briefings in bioinformatics·2025
Same author

Learning to utilize internal protein 3D nanoenvironment descriptors in predicting CRISPR-Cas9 off-target activity.

NAR genomics and bioinformatics·2025

Related Experiment Video

Updated: Sep 16, 2025

Author Spotlight: Affinity Purification of a Fibrinolytic Enzyme from Sipunculus nudus
06:45

Author Spotlight: Affinity Purification of a Fibrinolytic Enzyme from Sipunculus nudus

Published on: June 2, 2023

2.3K

Plasminogen Activator Inhibitors in Thrombosis: Structural Analysis and Potential Natural Inhibitors.

Roney V Dos Santos1,2, Manoel Victor Frutuoso Barrionuevo3, Mikael Rangel Fernandes Vieira4

  • 1School of Pharmaceutical Sciences, UNICAMP, Campinas, SP 13083-871, Brazil.

ACS Omega
|July 7, 2025
PubMed
Summary

Plasminogen activator inhibitors (PAIs) regulate blood clots. This study reveals PAI structural insights and identifies natural compounds like salvianolic acid B as potential treatments for thrombosis.

More Related Videos

Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment
10:59

Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment

Published on: November 23, 2017

12.4K
Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

22.0K

Related Experiment Videos

Last Updated: Sep 16, 2025

Author Spotlight: Affinity Purification of a Fibrinolytic Enzyme from Sipunculus nudus
06:45

Author Spotlight: Affinity Purification of a Fibrinolytic Enzyme from Sipunculus nudus

Published on: June 2, 2023

2.3K
Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment
10:59

Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment

Published on: November 23, 2017

12.4K
Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

22.0K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Thrombosis involves excessive blood clot formation, regulated by the fibrinolytic system.
  • Plasminogen activator inhibitors (PAIs), particularly PAI-1, PAI-2, and PAI-3, are key regulators of fibrinolysis.
  • Understanding PAI structures is crucial for developing targeted anticoagulant therapies.

Purpose of the Study:

  • To analyze the secondary and tertiary structures of PAI-1, PAI-2, and PAI-3.
  • To investigate their evolutionary relationships and conserved functional domains.
  • To identify natural product-derived inhibitors for potential anticoagulant therapies.

Main Methods:

  • Comprehensive structural analysis of PAI-1, PAI-2, and PAI-3.
  • Comparative phylogenetic analysis.
  • Structural superimposition and RMSD calculations.
  • Molecular docking and molecular dynamics simulations.

Main Results:

  • Detailed analysis of PAI-1, PAI-2, and PAI-3 secondary and tertiary structures.
  • PAI-2 and PAI-3 show closer structural similarity than PAI-1.
  • Salvianolic acid B and tanshinone IIA sulfate demonstrated high binding affinity and stability as potential inhibitors.

Conclusions:

  • Structural insights into PAIs aid in understanding their inhibitory mechanisms.
  • Natural compounds, specifically salvianolic acid B and tanshinone IIA sulfate, show promise as novel fibrinolytic agents.
  • Findings support the development of new therapeutic strategies for thrombotic disorders.